Viking Therapeutics Inc. (NASDAQ: VKTX) kicked off on January 24, 2023, at the price of $8.44, up 2.13% from the previous trading day. During the day, the shares moved up to $8.64 and dropped to $8.3312 before settling in for the closing price of $8.44. Over the past 52 weeks, VKTX has traded in a range of $2.02-$9.62.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
While this was happening, its average annual earnings per share was recorded -30.90%. With a float of $67.77 million, this company’s outstanding shares have now reached $76.50 million.
Considering the fact that the conglomerate employs 17 people, you should pay attention to its efficiency factor.
Viking Therapeutics Inc. (VKTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viking Therapeutics Inc. is 11.78%, while institutional ownership is 35.70%. The most recent insider transaction that took place on May 02, was worth 111,195. In this transaction Director of this company bought 45,000 shares at a rate of $2.47, taking the stock ownership to the 111,250 shares.
Viking Therapeutics Inc. (VKTX) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/29/2022, the organization reported -$0.21 earnings per share (EPS), higher than consensus estimate (set at -$0.23) by $0.02. This company achieved a return on equity of -24.65. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.00% during the next five years compared to 4.70% growth over the previous five years of trading.
Viking Therapeutics Inc. (NASDAQ: VKTX) Trading Performance Indicators
Take a look at Viking Therapeutics Inc.’s (VKTX) current performance indicators. Last quarter, stock had a quick ratio of 11.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.98 in one year’s time.
Technical Analysis of Viking Therapeutics Inc. (VKTX)
Compared to the last year’s volume of 1.87 million, its volume of 1.51 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 20.00%. Additionally, its Average True Range was 0.58.
During the past 100 days, Viking Therapeutics Inc.’s (VKTX) raw stochastic average was set at 85.89%, which indicates a significant increase from 38.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.33% in the past 14 days, which was lower than the 114.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.16, while its 200-day Moving Average is $3.81. Nevertheless, the first resistance level for the watch stands at $8.73 in the near term. At $8.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.04. If the price goes on to break the first support level at $8.42, it is likely to go to the next support level at $8.22. Should the price break the second support level, the third support level stands at $8.11.
Viking Therapeutics Inc. (NASDAQ: VKTX) Key Stats
The company with the Market Capitalisation of 664.08 million has total of 76,688K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -54,990 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -15,773 K.